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ABSTRACT 
RECQL4 helicase is a molecular motor that unwinds DNA, a process essential during DNA 
replication and DNA repair. Germ-line mutations in RECQL4 cause type II Rothmund-
Thomson syndrome (RTS) characterised by a premature aging phenotype and cancer 
predisposition. RECQL4 is widely considered as a tumour suppressor, although its role in 
human breast cancer is largely unknown.  As the RECQL4 gene is localized to chromosome 
8q24, a site frequently amplified in sporadic breast cancers, we hypothesised that it may play 
an oncogenic role in breast tumorigenesis. To address this we analysed large cohorts for gene 
copy number changes (n=1977), mRNA expression (n=1977) and protein level (n=1902). 
Breast cancer incidence was also explored in 58 patients with type II RTS. DNA replication 
dynamics and chemo-sensitivity was evaluated in RECQL4-depleted breast cancer cells in 
vitro. Amplification or gain in gene copy number (30.6%), high level mRNA expression 
(51%) and high levels of protein (23%) significantly associated with aggressive tumour 
behaviour including lymph node positivity, larger tumour size, HER2 over expression, ER-
negativity, triple negative phenotypes and poor survival. RECQL4 depletion impaired DNA 
replication rate and increased chemo-sensitivity in cultured breast cancer cells. Thus, 
although recognised as a “safe guardian of the genome”, our data provides compelling 
evidence that RECQL4 is tumour promoting in established breast cancers. 
 
Key words: RECQL4 helicase; breast cancer; tumour suppressor; oncogene. 
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INTRODUCTION 
 
DNA helicases are molecular motors that unwind DNA, an essential process required during 
DNA replication and DNA repair.  RecQ Protein-Like 4 (RECQL4) is a key member of the 
RecQ family of DNA helicases and plays an important role in the maintenance of genomic 
stability [1-3]. RECQL4 has a role in the initiation of DNA replication, progression of stalled 
replication forks, telomere maintenance and in repair of DNA double-strand breaks (DSBs) 
via the homologous recombination (HR) pathway [1-3]. Mutations in the RECQL4 gene are 
found in about two-thirds of all cases of Rothmund-Thomson syndrome (RTS), and these 
patients are designated as having Type II RTS [4, 5].  RTS is characterised by a premature 
aging and predisposition to cancers, especially lymphomas and osteosarcomas [4, 5]. A 
tumour suppressor function of RECQL4 has been widely described, although recent evidence 
also suggests a tumour-promoting role for RECQL4. In preclinical studies, we have recently 
found overexpression of RECQL4 in prostate cancer cell lines, and depletion of RECQL4 by 
siRNA or shRNA vectors significantly reduced the growth and survival of metastatic prostate 
cancer cells [6].  Similarly, in breast cancer cell lines, we have observed overexpression of 
RECQL4, and found that depletion of RECQL4 promoted apoptosis [7]. Interestingly, the 
RECQL4 gene is localized to chromosome 8q24, a site frequently amplified in sporadic 
breast cancers [8-10].  We therefore hypothesised a tumour-promoting role for RECQL4 in 
breast cancers.  
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MATERIALS AND METHODS 
 
RECQL4 gene copy number changes and mRNA levels: The METABRIC (Molecular 
Taxonomy of Breast Cancer International Consortium) cohort [11] was evaluated for 
RECQL4 gene copy number changes and mRNA levels. Patient demographics are 
summarized in supplementary Table S1 and full methods are discussed in Supplementary 
Methods online.  
RECQL4 protein expression in breast cancer: The study was performed in two cohorts of 
breast cancers.  The first cohort was a consecutive series of 1,650 patients with primary 
invasive breast carcinomas who were diagnosed between 1986 and 1999.  The second cohort 
was an independent series of 252 ER-α negative invasive breast cancer patients diagnosed 
and managed at the Nottingham University Hospitals between 1999 and 2007.  
Immunohistochemical evaluation of RECQL4 is summarized fully in Supplementary 
methods and Supplementary Table S6. Tumour Marker Prognostic Studies (REMARK) 
criteria, recommended by McShane et al [12], were followed throughout this study.  Ethical 
approval was obtained from the Nottingham Research Ethics Committee (C202313).  
Breast cancer assessment in RTS patients:  Incidence of breast cancer was evaluated 
among a cohort of RTS patients enrolled in a longitudinal clinical research study approved by 
the Institutional Review Board for Human Subjects Research at Baylor College of Medicine 
(Houston TX).  All subjects or parents provided informed written consent to participate in the 
study.   Clinical information was updated by yearly questionnaires. RTS patients with known 
mutations in the RECQL4 gene (Type II RTS) were included in the present study (n=58). 
Patient demographics are shown in Supplementary Table S7.  
Cell line studies: HeLa, MCF7, MDA-MB-231 and BT549 lines were obtained from the 
ATCC (Manassas, VA, USA). Detailed methodology for Western blotting and 
imunofluorescence is summarised in Supplementary methods. We generated transient 
RECQL4 knockdown as well as stable RECQL4 knockdowns in breast cancer cells as 
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described in Supplementary Methods. Cell numbers were estimated by the MTT assay 
according to the manufacturer’s protocol. To evaluate replication dynamics, DNA fibre 
assays were performed as described previously [13]. Detailed methodology is also described 
in Supplementary Methods.  
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RESULTS AND DISCUSSION 
 
 
We have recently shown that RECQL4 gene amplification and elevated levels of RECQL4 
expression are common in breast cancer cell lines [7]. Moreover, depletion of RECQL4 not 
only reduced breast cancer cell proliferation but also impaired tumourigenicity in tumour 
bearing mice [7]. These data therefore support that RECQL4 may be oncogenic and drive 
breast tumourigenesis. To test this hypothesis, we conducted a comprehensive clinical study. 
 
RECQL4 gene amplification or gain in copy number changes in breast cancers: None of 
1970 (0%) tumours had RECQL4 homozygous deletion, 19/1970 (1%) of tumours had 
RECQL4 heterozygous deletion, 1348/1970 (68.4%) of tumours had RECQL4 neutral gene 
copy number, 543/1970 (27.6%) of tumours had gain in RECQL4 copy number and 60/1970 
(3%) of tumours had amplification of the RECQL4 gene. We grouped gain/amplification and 
homozygous deletion/heterozygous/neutral together. As shown in Supplementary Figure 1A, 
ER-  tumours were more likely to have gain/amplification of RECQL4 compared to ER+ 
tumours (p=0.0003). Within the various molecular phenotype groups, compared to normal 
phenotype, tumours that were PAM50.Basal (p<0.00001), or PAM50.HER2 (p<0.00001) had 
significantly grreater gain/amplification of RECQL4 (Figure 1A). Within the ER+ sub-group, 
PAM50.Luminal B sub-groups had significantly greater gain/amplification of RECQL4 
(Figure 1A) compared to PAM50.Luminal A sub-group (p<0.00001) (Figure 1A).  As shown 
in Supplementary Table S5, high stage, grade 3 tumours and lymph node positivity were 
more common in tumours with gain/amplification of RECQL4. As expected, breast cancer 
specific survival (BCSS) was worse in tumours with gain/amplification of RECQL4 
compared to tumours with neutral changes or loss of RECQL4 (p<0.00001) (Figure 1B).  
 
High levels of RECQL4 transcripts in breast cancers: 966/1977 (49%) of tumours had low 
RECQL4 mRNA levels and 1011/1977 (51%) tumours had high RECQL4 mRNA levels. ER- 
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tumours had higher RECQL4 mRNA levels compared to ER+ tumours (p<0.0001) 
(Supplementary Figure 1B). Within the various molecular phenotype groups, compared to 
normal phenotype, tumours that were PAM50.Basal (p<0.00001), or PAM50.HER2 
(p<0.00001) had high RECQL4 mRNA levels (Figure 1C). High levels of RECQL4 mRNA 
were highly significantly associated with aggressive clinicopathological features (Table 1) 
including high histological grade, lymph node positivity, larger tumour size, Nottingham 
prognostic index (NPI) >3.4, and triple negative phenotype (each, p<0.001). High RECQL4 
mRNA level was also found to be significantly associated with previously described 
molecular phenotypes in breast cancer: Genufu subtype (ER-/HER2-) (p<0.00001), Genufu 
subtype (ER+/HER2-/High proliferation) (p<0.00001) and Genufu subtype (HER2 positive) 
(p = 0.001) breast tumours. However, PAM50.Luminal A tumours and Genufu subtype 
(ER+/HER2-/low proliferation) were more likely to have low levels of RECQL4 mRNA 
(each, p<0.00001). A high level of RECQL4 mRNA in the tumour was associated with poor 
breast cancer specific survival (BCSS) (p<0.00001) (Figure 1D).  In multivariate Cox 
regression analysis RECQL4 mRNA levels remained independently associated with poor 
BCSS (p<0.00001) (Supplementary Table S6).  
 
Mechanistic insights: As shown in Figure 2A, there was a strong correlation between gene 
copy number changes and mRNA levels (p<0.00001). The correlation remains significant 
across various sub-groups including in ER- (p<0.0001), ER+ (p<0.0001), PAM50.Basal 
(p<0.0001), PAM50. HER2 (p<0.0001), PAM50.Luminal A (p<0.0001) and 
PAM50.Luminal B tumours (p<0.0001) (Supplementary Figures S1C and S1D). Taken 
together the data supports that in a proportion of aggressive tumours, a high mRNA level is 
due to increased gene copy number. 
 
RECQL4 protein level in breast cancers: The N-terminal region of RECQL4 contains the 
nuclear as well as mitochondrial targeting sequences and is important for sub-cellular 
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localisation of RECQL4 [1-3]. In addition, post-translational modification (such as 
acetylation) of RECQL4 may also alter its sub-cellular localisation [1-3]. As expected, we 
observed complex sub-cellular localisation of RECQL4 in human breast cancers including 
exclusively nuclear staining (17.6%), exclusively cytoplasmic staining (23.4%), nuclear-
cytoplasmic co-expression (24.8%) or absence of staining (34.2%) (Supplementary Figure 
S1E).  In 20 normal breast tissues, however, we observed exclusively nuclear staining in all 
samples and no cytoplasmic staining (Supplementary Figure S1E) implying that altered sub-
cellular localisation is a feature of cancer and not normal tissue. Tumours with high 
cytoplasmic/low nuclear RECQL4 levels were significantly associated with high grade, high 
mitotic index, pleomorphism, NPI>3.4, ER-, and triple negative phenotype (all p values 
<0.01) (Supplementary Table S7) and poor survival (p=0.042) (Figure 2B). In multivariate 
analysis the RECQL4 protein level independently influenced survival (p=0.032) 
(Supplementary Table S8).  
 
Breast cancer incidence in patients with Rothmund-Thomson Syndrome (RTS): 
Germline mutation in RECQL4 is causal for two-thirds of patients with Type II RTS, and it 
has previously been shown that RECQL4 mutation status correlates with risk of developing 
osteosarcoma [4, 5]. In the largest available cohort of type II RTS patients, we did not 
observe any increased incidence of breast cancers.  The data suggests that either RECQL4 
deficiency does not influence breast cancer pathogenesis or that RTS patients have not lived 
long enough to develop breast cancer. 
 
Depletion of RECQL4 significantly reduced DNA replication rates and increased 
sensitivity to chemotherapy: DNA synthesis rates were measured using a DNA fibre assay 
after BrdU incorporation in MCF7, MDA-MB-231 and BT549 breast cancer cell lines plus or 
minus control siRNA or siRNA to deplete RECQL4 (Supplementary Figure S2). We 
consistently observed shorter DNA fibre lengths after depletion of RECQL4 in the breast 
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cancer cells (Figure 2C and 2D). We then generated a stable RECQL4 knock down ER- 
(MDA-MB- 453) breast cancer cell line (Figure 3A). As shown in Figures 3B- 3D, RECQL4 
depleted breast cancer cells were sensitive to treatment with cisplatin, doxorubicin or 5-FU.  
 
In conclusion, we have demonstrated that high copy number, high mRNA levels and high 
protein levels of RECQL4 is associated with aggressive breast cancers. Although the data 
suggest to us that RECQL4 has oncogenic potential, it is also possible that RECQL4 
overexpression may be a secondary event that may allow cancer cells to maintain high 
proliferation rate and telomere elongation required for cancer cell survival. 
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Table 1: Association between RECQL4 mRNA expression and clinicopathological variables in the METABRIC 
cohort. 
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VARIABLE 
 
 
RECQL4 mRNA levels  
 
 
 P Value 
 
Low High 
N(%) N (%) 
 
A) Pathological    Parameters 
Lymph node involvement    
Negative 537 (55.9%) 498 (49.3%) 0.003 
 Positive (1-3) 129 (13.4%) 185 (18.3%) 
Positive (>3) 295 (30.7%) 327 (32.4%) 
Grade 
G1 137 (15.0%) 32 (3.3%) 2.4x10
-47
 
G2 466 (51.2%) 304 (31.1%) 
G3 308 (33.8%) 642 (65.6%) 
Tumour size (cm) 
T 1a+b(1.0) 58 (6.0%) 34 (3.4%) 1.3x10
-5
 
T 1c(>1.0-2.0) 413 (43.1%) 353 (35.4%) 
T2 (>2.0-5) 450 (46.9%) 551 (55.2%) 
T3 (>5) 38 (4.0%) 60 (6.0%) 
NPI 
≤ 3.4 298 (35.3%) 120 (12.4%) 7.2x10-27 
>3.4 603 (66.9%) 849 (87.6%) 
 
HER2 overexpression (No)  883 (91.4%) 849 (84.0%) 5.3x10
-7
 
                              (Yes) 83 (8.6%) 162 (16.0%) 
Triple negative          (No)        866 (89.6) 794 (78.5) 1.6x10
-11
 
                               (Yes)  100 (10.4) 217 (21.5) 
ER                   (Negative) 156 (16.1%) 314 (31.1%) 7.0x10
-15 
                       (Positive) 810 (83.9%)  697 (68.9%) 
PgR                  (Negative) 359 (37.2%) 577 (57.1%) 7.8x10
-19
 
                         (Positive) 607 (62.8%) 434 (42.9%) 
Genefu subtype 
ER-/HER2 negative 47 (9.8%) 103 (20.0%) 6.0x10
-6
 
ER+/HER2 negative/high 
proliferation 
97 (20.2%) 269 (52.3%) 9.2x10
-26
 
ER+/HER2 negative/low 
proliferation 
299 (62.3%) 69 (13.4%) 3.1x10
-57
 
HER2 positive 37 (7.7%) 73 (14.2%) 0.001 
PAM50 subtype 
PAM50.HER2 66 (8.1%) 172 (17.9%) 1.9x10
-9
 
PAM50.Basal   90 (11.1%) 240 (25.0%) 7.6x10
-14 
PAM50.LumA 515 (63.5%) 200 (20.8%) 2.1x10
-74 
PAM50.LumB 140 (17.3%) 349 (36.3%) 3.9x10
-19
 
Bold = Statistically significant;HER2: human epidermal growth factor receptor 2; ER: oestrogen receptor; PgR: 
progesterone receptor; Triple negative: ER-/PgR-/HER2- . High proliferation = high Ki67 index, Low 
proliferation = low Ki67 index.   
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Figure legends 
 
Figure 1. RECQL4 copy number, mRNA and protein levels in breast cancer. A. RECQL4 
gene copy number changes in PAM50. Molecular phenotypes.  B.  Kaplan Meier curves 
showing BCSS (breast cancer specific survival) in the whole cohort. C. RECQL4 mRNA 
levels in PAM50. Molecular phenotypes. D. Kaplan Meier curves showing BCSS (breast 
cancer specific survival) in the whole cohort.   
 
Figure 2. A. Correlation between RECQL4 gene copy number and mRNA levels in the 
whole cohort. B. Kaplan Meier curves showing BCSS based on RECQL4 protein levels in 
the whole cohort. C. Effects of RECQL4 knockdown using siRNA on DNA synthesis 
assessed by DNA fibre assay (see Supplementary Methods for details). D. In MCF7 and 
MDA-MB-231 cells DNA fibre lengths were reduced by around 50% after RECQL4 
knockdown. Compared with the other two lines, BT549 cells showed shorter fibre tracks to 
begin with, but like the other cells, RECQL4 depletion further reduced the rate of synthesis of 
DNA 
 
Figure 3. RECQL4 depletion and chemosensitivity to chemotherapeutic drugs in MDA-
MB453 cells. RECQL4 knockdown by adenovirus-mediated shRNA  (A) and treatment with 
cisplatin (B), doxorubicin (C) or 5-FU (D). Cell survival was measured by the 3-(4,5-
dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay following the 
manufacturer's instructions (Molecular Probes). Absorbance values at 540 nm were read on a 
Spectra Max 250 spectrophotometer (Molecular Devices). All MTT assays include 10 
duplicated wells for each time-point of each cell line. The data was represented as mean ± SD 
from three independent experiments. *, P<0.05; **, P<0.01. 
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Supplementary Table S1:  Clinicopathological characteristics in the METABRIC external validation cohort  
Variables N (%) 
Age at diagnosis [Median (range)] 61.8 (21.93-96.29) 
Tumour size [Median (range)] 23 (1, 182) 
NPI [Median (95% CI)] 4.04 (3.99-4.09) 
Survival [Median (Months, 95% Cl)] 149 (141-159) 
Lymph nodes status 
 
0 
1 
2 
3 
>3 
 
 
 
1012 
336 
170 
112 
316 
ER status 
 
Positive 
Negative 
 
 
 
1485 
437 
PAM50 subtype 
 
Basal  
HER2  
Luminal A  
Luminal B  
Normal  
Not classified 
 
 
 
322 
238 
714 
484 
188 
6 
Adjuvant systemic therapy (AT)  
No AT  290 
Hormone therapy (HT) 1014 
Chemotherapy 226 
Hormone + chemotherapy 192 
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Supplementary Table S2: Clinicopathological characteristics of Nottingham Tenovus series 
 
Variable n* Cases          (%) 
Menopausal status 1650  
Pre-menopausal  612          (37.0) 
postmenopausal  1038        (63.0) 
Tumour Grade (NGS) 1650  
G1   306          (18.5) 
G2  531          (32.2) 
G3   813          (49.3) 
Lymph node involvement 1650  
Negative   1056         (64.0) 
Positive (1-3 nodes)  486          (29.5) 
Positive (>3 nodes)  108           (6.5) 
Tumour size (cm) 1650  
T1 a + b (≤1.0)  187         (11.0) 
T1 c (>1.0 -2.0)  868         (53.0) 
T2 (>2.0-5)  579      (35.0) 
T3 (>5)  16         (1.0) 
Tumour type 1650  
IDC-NST  941         (57) 
Tubular   349         (21) 
ILC  160        (10) 
Medullary (typical/atypical)  41          (2.5) 
Others  159        (9.5) 
NPI subgroups 1650  
Excellent prognosis (2.08-2.40) Low risk 207         (12.5) 
Good prognosis (2.42-3.40) 331          (20.1) 
Moderate I prognosis (3.42 to 4.4) High risk 488         (29.6) 
Moderate II prognosis (4.42 to 5.4) 395         (23.9) 
Poor prognosis (5.42 to 6.4) 170         (10.3) 
Very poor prognosis (6.5–6.8) 59         (3.6) 
19 
 
Survival at 20 years 1650  
Alive and well  1055         (64.0) 
Dead from disease  468          (28.4) 
Dead from other causes  127         (7.6) 
Adjuvant systemic therapy (AT)   
No AT   665         (42.0) 
Hormone therapy (HT)  642         (41.0) 
Chemotherapy  307         (20.0) 
Hormone + chemotherapy  46         (3.0) 
* Number of cases for which data were available. 
NPI; Nottingham prognostic index. 
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Supplemental Table S3: Clinicopathological characteristics of ER- cohort 
Variable n* Cases          (%) 
Menopausal status 252  
Pre-menopausal  122      (48.5) 
postmenopausal  130      (51.5) 
Tumour Grade (NGS) 252  
G1     1         (0.3) 
G2    27        (10.6) 
G3  224        (89.1) 
Lymph node involvement 252  
Negative    121       (48) 
Positive (1-3 nodes)     86       (34) 
Positive (>3 nodes)      45      (18) 
Tumour size (cm) 252  
T1 a + b (≤1.0)   28        (11) 
T1 c (>1.0 -2.0)  106       (42) 
T2 (>2.0-5)  103       (41) 
T3 (>5)   15       (6) 
Tumour type 252  
IDC-NST  224        (89.0) 
Tubular   5            (2.0) 
ILC  8            (3.0) 
Medullary (typical/atypical)  5            (2.0) 
Others  0            (4.0) 
NPI subgroups 252  
Excellent prognosis (2.08-2.40) Low risk 0           (0.0) 
Good prognosis (2.42-3.40) 0           (0.0) 
Moderate I prognosis (3.42 to 4.4) High risk 111       (44.0) 
Moderate II prognosis (4.42 to 5.4) 81         (32.0) 
Poor prognosis (5.42 to 6.4) 38         (15.0) 
Very poor prognosis (6.5–6.8) 22         (9.0) 
21 
 
Survival at 5 years 252  
Alive and well  176      (70.0) 
Dead from disease    73      (29.0) 
Dead from other causes     3       (1.0) 
* Number of cases for which data were available. 
NPI; Nottingham prognostic index. 
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Supplementary Table S4: RTS patient’s demographics. 
 
Rothmund-Thomson Syndrome (Type II) 
   All Female Male 
  n=58 n=24 n=34 
Age, median (range) 17.5 yrs (10 mos - 51 yrs) 13 yrs (10 mos - 40 yrs) 18.5 yrs (10 mos - 51 yrs) 
<40 years old, n (%) 55 (94.8%) 23 (95.8%) 32 (94.1%) 
Follow-up, median (range) 12 yrs (10 mos - 42 yrs) 10 yrs (10 mos - 37 yrs) 16 yrs (10 mos - 42 yrs) 
23 
 
Supplementary Table S5: RECQL4 gene copy number alterations in  the METABRIC cohort (n=1980) 
 
 
 RECQL4 Gene Copy Number changes 
 HETD 
N(%) 
NEUT 
N(%) 
GAIN 
N(%) 
AMP 
N(%) 
P value 
Stage  
 
1 5 (35.7) 369 (36.9) 121(30.9) 6(14.0) 0.036 
2 8 (57.1) 556 (55.6) 225(57.5) 31(72.1)  
3 1 (7.2) 69 (6.9) 41(10.5) 6(13.9)  
4 0 (0.0) 6 (0.6) 4(1.1) 0(0.0)  
Grade 
 
G1 0 (0.0) 143 (11.2) 25 (4.7) 1(1.8) 0.0001 
G2 8 (44.4) 576 (45.0) 160(30.4) 21(37.5) 
G3 10(55.6) 562 (43.8) 342(64.9) 34(60.7) 
Lymph node involvement 
 
Negative 11(57.9) 739 (54.8) 268(49.4) 22(36.7) 0.01 
Positive 8(42.1) 609(45.2) 275(50.6) 38(63.3) 
PAM50 subtype 
 
PAM50.Her2 2(10.5) 151(12.8) 75(14.5) 11(19.6) 0.00001 
PAM50.Basal   6(31.6) 194(16.5) 117(22.7) 10(17.9) 
PAM50.LumA 3(15.8) 561(47.7) 143(27.7) 8(14.3) 
PAM50.LumB 8(42.1) 270(23.0) 181(35.1) 27(48.2) 
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Supplementary Table S6: Multivariate analysis in the METABRIC cohort confirms that RECQL4 mRNA over 
expression is a powerful independent prognostic factor. 
 P-Value HR 95% CI for HR 
Lower Upper 
Breast Cancer Specific Survival 
RECQL4 Expression 0.000015 1.366 1.185 1.573 
NPI 0.00016 1.319 1.142 1.524 
Tumour Grade 
G1 
G2 
G3 
 
0.039 
0.246 
0.178 
 
0.893 
0.992 
1.357 
 
0.538 
0.629 
0.734 
 
1.481 
1.563 
2.509 
LN involvement 
LN (1-3) 
LN(>3) 
 
0.00046 
0.312 
 
1.980 
1.277 
 
1.328 
0.973 
 
2.950 
1.678 
 
  
Bold: Statistically significant; HR: Hazard Ratio; CI: Confidence interval; LN: Lymph node; NPI: Nottingham 
Prognostic Index. 
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Supplementary Table S7.  RECQL4 nuclear and cytoplasmic co-expression and breast cancer.  
 
   
 
                    VARIABLE 
 
RECQL4(Nuclear & Cytoplasmic) Protein Co-
expression 
 
 
 
P- value 
 
Rn-/RC- 
N (%) 
Rn+/RC- 
N (%) 
 
Rn-/Rc+ 
N (%) 
 
Rn+/Rc+ 
 
A) Pathological    Parameters 
Tumour Size  
 ≤1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
 31 (9.1) 
171 (50.0) 
133 (38.9) 
7 (2.0) 
 
17 (9.6) 
94 (52.8) 
62 (34.8) 
5 (2.8) 
 
25 (10.6) 
110 (46.6) 
96 (40.7) 
5 (2.1) 
 
25 (10.0) 
132 (53.0) 
88 (35.3) 
4 (1.6) 
 
0.927 
Tumour Stage                                 
1 
2 
3 
 
209 (60.8) 
102 (29.7) 
33 (9.6) 
 
109 (61.2) 
53 (29.8) 
16 (9.0) 
 
142 (60.4) 
73 (31.1) 
20 (8.5) 
 
165 (66.0) 
69 (27.6) 
16 (6.4) 
 
0.785 
Tumour Grade                              
 G1 
 G2 
 G3 
  
55 (16.0) 
101 (29.4) 
187 (54.5) 
 
26 (14.6) 
83 (46.6) 
69 (38.8) 
 
35 (14.8) 
62 (26.3) 
139 (58.9) 
 
42 (16.9) 
82 (32.9) 
125 (50.2) 
 
0.001 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
100 (29.9) 
69 (20.6) 
166 (49.6) 
  
88 (49.4) 
27 (15.2) 
63 (35.4) 
 
58 (25.6) 
33 (14.5) 
136 (59.9) 
 
315 (32.1) 
196 (20.0) 
471 (48.0) 
 
1.4X10
-8
 
Tubule Formation                          
1 (>75% definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
20(6.0) 
102 (30.4) 
213 (63.6) 
 
8 (4.5) 
60 (33.7) 
110 (61.8) 
 
10 (4.4) 
78 (34.4) 
139 (61.2) 
 
54 (5.5) 
336 (34.2) 
592 (60.3) 
 
0.282 
Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
11 (3.3) 
120 (35.9) 
203 (60.8) 
 
2 (1.1) 
83 (46.9) 
92 (52.0) 
 
1 (0.4) 
74 (32.7) 
151 (66.8) 
 
5 (2.1) 
87 (36.0) 
150 (62.0) 
 
0.014 
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
ILC 
Others 
Mixed NST/Lobular/Special 
Type 
 
221 (65.8) 
62 (18.5) 
9 (2.7) 
19 (5.7) 
6(61.8) 
19 (5.7) 
 
90 (50.8) 
35 (19.8) 
2 (1.1) 
35 (19.8) 
3 (1.7) 
12 (6.8) 
 
143 (62.2) 
49 (21.3) 
11 (4.8) 
10 (4.3) 
1 (0.4) 
16 (7.0) 
 
152 (62.6) 
59 (24.3) 
4 (1.6) 
12 (4.9) 
2 (0.8) 
14 (5.8) 
 
6.7x10
-7
 
Lymph Node involvement                   
Negative 
Positive (1-3) 
Positive (>3) 
180 (59.6) 
97 (32.1) 
25 (8.3) 
 
102 (60.4) 
55 (32.5) 
12(7.1) 
 
114 (57.3) 
71 (35.7) 
14 (7.0) 
 
145 (63.9) 
73 (32.2) 
9 (4.0) 
 
0.530 
B) Aggressive Phenotype 
Her2 overexpression                     
No 
Yes 
284 (84.0) 
54 (16.0) 
 
151 (86.8) 
23 (13.2) 
 
191 (82.3) 
41 (17.7) 
 
203 (83.2) 
41(16.8) 
 
0.662 
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Triple Negative Phenotype               
No 
Yes 
294 (85.2) 
51 (14.8) 
 
162 (91.0) 
16 (9.0) 
 
184 (78.0) 
52 (22.0) 
 
198 (79.2) 
52 (20.8) 
 
0.001 
NPI           
≤3.4 
>3.4 
 
97 (29.8) 
229 (70.2) 
 
67 (39.6) 
102 (60.4) 
 
54 (24.0) 
171 (76.0) 
 
 
75 (31.1) 
166 (68.9) 
 
0.010 
C) Hormone Receptors 
ER               
Negative 
Positive 
 
105 (31.4) 
229 (68.6) 
 
30 (17.0) 
146 (83.0) 
 
75 (32.8) 
154 (67.2) 
 
54 (22.5) 
186 (77.5) 
 
3.4X10
-4
 
PgR                                   
Negative 
Positive 
 
162 (49.4) 
166 (50.6) 
 
65 (38.5) 
104 (61.5) 
 
108 (47.2) 
121 (52.8) 
 
84(36.2) 
148 (63.8) 
 
0.006 
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Supplementary Table S8: RECQL4 protein expression and survival – Multivariate Analysis 
 
 P value Exp (B) 95%  CI of Exp (B) 
   Lower Upper 
Breast cancer specific Survival 
RECQL4 (Nuclear ) 
0.032 0.753 0.581 0.976 
RECQL4 (Cyto) 
0.352 1.126 0.877 1.446 
Tumour Grade 
3.0 x 10
-6 1.718 1.370 2.155 
Lymph Node involvement 
5.6 x 10
-12
 1.980 1.630 2.404 
Tumour Size 
0.061 1.211 0.991 1.478 
ER Status 
0.698 1.061 0.788 1.428 
HER2 Status 
0.001 1.686 1.246 2.280 
Endocrine Therapy 
0.072 1.239 0.981 1.564 
Chemotherapy 
0.410 1.153 0.821 1.620 
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Supplementary Figure legends 
 
Supplementary Figure S1. A, RECQL4 gene copy number changes in ER+ and ER- breast 
cancers. B, RECQL4 mRNA expression in ER+ and ER- breast cancers. C, Correlation between 
RECQL4 gene copy numbers and mRNA expression based on ER status (C) and PAM50. D, 
Molecular phenotypes. E, Photomicrographs showing RECQL4 protein expression and sub-
cellular localisation in tumour tissue and normal breast tissue. N= nuclear staining, C= 
cytoplasmic staining, ‘+’ = positive for staining, ‘-‘ = negative for staining]. 
 
Supplementary Figure S2. RECQL4 knockdown using siRNA.  
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